Global biopharmaceutical company UCB Pharma will join forces with the University of Oxford in the UK to develop medicines that will treat serious diseases in immunology and neurology.
UCB, which has already invested heavily in research and development in the UK, will fund the collaboration with £3.6 million over three years.
A steering committee of UCB and Oxford University representatives will oversee the collaboration via regular meetings to scope out and monitor new projects.
Between five and ten projects will be selected for investigation over the course of the agreement.
UCB chief executive Roch Doliveux said: "This new partnership combines Oxford University’s world-class academic research with UCB’s world-class antibody research to bring two parties, committed to scientific exploration and the exchange of cutting edge ideas, together on a mission to discover new medicines that will aim to transform the lives of people living with severe diseases."
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
Regius Professor of Medicine at Oxford University Sir John Bell said: "I am eager to see the research that results. Partnerships between industry and academia will have an increasingly prominent role to play in the development of new drugs, therapies and medical technologies."
Image: UCB Pharma and the University of Oxford will work together to develop medicines. Credit: Marti157900